Description
CD40L (human) (multimeric) (rec.) | AG-40B-0010-C010
MultimericCD40L™ is a high activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations. MultimericCD40L™ has shown to suppress alum-induced IL-1β release and caspase-1 activation in a dose-, CD40- and time dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced.
Product Details | |
---|---|
Synonyms | MultimericCD40L™; ACRP30headless:CD40L; ACRP30headless:CD154; ACRP30headless:TNFSF5; ADIPOQ-CD40L |
Product Type | Protein |
Properties | |
Source/Host | CHO cells |
Sequence |
Human CD40L (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag. |
Crossreactivity | Human |
Specificity |
Binds to human CD40. |
Biological Activity |
Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED50: <1ng/ml). B cell expansion online protocol available. |
MW | ~35-40kDa (SDS-PAGE) |
Purity | ≥95% (SDS-PAGE) |
Endotoxin Content | <0.01EU/μg purified protein (LAL test, Lonza). |
Concentration | 0.1mg/ml after reconstitution. |
Reconstitution | Reconstitute with 100μl sterile water. |
Formulation | Lyophilized. Contains PBS |